|1.||Nawa, Akihiro: 4 articles (02/2010 - 03/2007)|
|2.||Iwaki, Masahiro: 4 articles (02/2010 - 03/2007)|
|3.||Tanino, Tadatoshi: 4 articles (02/2010 - 03/2007)|
|4.||Nishiyama, Yukihiro: 3 articles (02/2010 - 03/2007)|
|5.||Kikkawa, Fumitaka: 3 articles (02/2010 - 03/2007)|
|6.||Ino, Kazuhiko: 2 articles (02/2010 - 02/2008)|
|7.||Shibata, Kiyosumi: 2 articles (02/2010 - 02/2008)|
|8.||Tsurumi, Tatsuya: 2 articles (02/2010 - 03/2007)|
|9.||Kajiyama, Hiroaki: 2 articles (02/2010 - 02/2008)|
|10.||Yamamoto, Eiko: 2 articles (02/2010 - 02/2008)|
|1.||Ovarian Neoplasms (Ovarian Cancer)
07/01/2008 - "The Ra-CES enzyme is capable of hydrolysing TAX-2'-Et, which may be beneficial for the development of a TAX-2'-Et/enzyme therapy strategy for ovarian cancer."
02/01/2008 - "We herein provide evidence that TAX-2'-Et could circumvent P-gp-associated cellular efflux of TAX, suggesting that this combination therapy is a potential GDEPT strategy for ovarian cancer in the future. "
02/01/2010 - "This GDEPT system aims to produce high level of CES at the tumor site, resulting in efficient local conversion of the TAX-2'-Et prodrug into the active drug TAX [A. "
03/01/2007 - "The TAX-2'-Et prodrug efficiently increased the amount of intracellular TAX, which mediates tumor cell death."
03/01/2007 - "TAX-2'-Et is converted into TAX by the Ra-CES, supporting its potential use as a theoretical GDEPT strategy for cancer cells expressing high levels of P-gp. "
03/01/2007 - "Transfection of Ra-CES into another TAX-resistant ovarian carcinoma cells (KOC-7c) conferred a high level of TAX-2'-Et cytotoxicity via prodrug activation. "
03/01/2007 - "TAX-2'-Et transport was characterized in a human colon carcinoma cell line (Caco-2) and paclitaxel (TAX)-resistant ovarian carcinoma cells (SKOV3/TAX60). "